首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Lancet Oncology

Lancet Oncology杂志,由Lancet Publishing Group出版,于2000年创刊,Monthly,出版语言English,ISSN:1470-2045,E-ISSN:1474-5488。

投稿咨询
Lancet Oncology
Lancet Oncology
Lancet Oncology
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
1区
影响因子
33.7
CiteScore
42
期刊收录
SCI、SCIE

Lancet Oncology(中文译名:《柳叶刀肿瘤学》),ISSN:1470-2045,EISSN:1474-5488,是Lancet Publishing Group出版的国际性学术期刊,创刊于2000年,以Monthly形式稳定发行,2026年总发文量约174篇。该刊采用非OA开放访问,学科归属为医学 - 肿瘤学。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达33.7,2025年期刊CiteScore为42,2025年期刊自引率约1.8%,在中科院期刊分区体系中位列医学大类1区TOP 期刊,在所属学科领域具备高学术影响力与国际认可度。Lancet Oncology长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期一般,3-8周,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USAEngland、France、Italy、GERMANY (FED REP GER)、Canada、Australia等为核心发文国家与地区;HARVARD UNIVERSITYUNICANCER、UNIVERSITY OF LONDON、UNIVERSITY OF TEXAS SYSTEM、UNIVERSITY OF CALIFORNIA SYSTEM、MEMORIAL SLOAN KETTERING CANCER CENTER、UNIVERSITY OF TORONTO等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
1区
是 否

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
1区
是 否

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
1区
是 否

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 9 / 333

97.4

学科:ONCOLOGY SCIE Q1 6 / 333

98.35

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 8 / 328

97.7

学科:ONCOLOGY SCIE Q1 4 / 328

98.93


中国学者近期发文

1
Fulzerasib plus cetuximab in first-line KRASG12C-mutated nonsmall-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 tria

Author:Gregorc, Vanesa; Majem, Margarita; Lo Russo, Giuseppe; Maio, Michele; Salvagni, Stephanie; Gutiérrez-Calderon, Vanesa; Gonzalez-Cao, Maria; Contreras, Sergio Sandiego; Koumarianou, Anna; Bearz, Alessandra; Bernabé-Caro, Reyes; Viteri, Santiago; de Sanmamed, Miguel Fernández; Zagouri, Flora; Bueno, Teresa Morán; Lazzari, Chiara; Martínez-Recio, Sergio; Giménez-Capitán, Ana; Zhang, Yue; Shan, Yue; Zhu, Huaqiang; Zhao, Congqiao; Shen, Haige; Wang, Yu; Rosell, Rafael

Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 4, pp. 432-441. DOI: 10.1016/S1470-2045(25)00764-8

2
Benmelstobart plus anlotinib versus pembrolizumab as first line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3tria

Author:Zhong, Hua; Wang, Jing; Yang, Runxiang; Luo, Yongzhong; Zuo, Wei; Zhang, Wei; Xie, Chao; Li, Qingshan; Liu, Qiang; Xu, Xingxiang; Wang, Qiming; Yu, Yan; Chen, Yongxing; Yi, Tienan; Min, Xuhong; Shi, Jinsheng; Yang, Jian; Sun, Hongmei; Chen, Hualin; Shi, Huaqiu; Gao, Junzhen; Shi, Jianhua; Zhang, Bo; Chu, Tianqing; Li, Kai; Han, Baohui

Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 4, pp. 419-431. DOI: 10.1016/S1470-2045(26)00049-5

3
Fuzuloparib plus apatinib in BRCAmutated breast cancer: balancing efficacy and accessibility in regional Chin

Author:Qiu, Ziran; Jin, Na

Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 3, pp. e125-e125. DOI: 10.1016/S1470-2045(25)00752-1

4
Fuzuloparib plus apatinib in BRCA- mutated breast cancer: balancing efficacy and accessibility in regional Chin

Author:Liu, Jieqiong; Liu, Yaxin; Song, Erwei; Li, Huiping

Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 3, pp. e126-e126. DOI:

5
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised double-blind, phase 3 stud

Author:Dummer, Reinhard; Guo, Jun; Luke, Jason J.; Carlino, Matteo S.; Schadendorf, Dirk; Khattak, Muhammad A.; Hauschild, Axel; Ascierto, Paolo A.; Chen, Yu; Shin, Sang Joon; Rutkowski, Piotr; Luo, Zhiguo; Chen, Jing; Rivalland, Gareth; Coetzee, Corlia; Ribas, Antoni; Mujika, Karmele; Markel, Gal; Villarroel, Rodrigo U.; Dizdar, Omer; Caglevic, Christian; Grebennik, Dmitri; Donovan, Kevin; Krepler, Clemens; Long, Georgina, V

Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 3, pp. 327-339. DOI: 10.1016/S1470-2045(25)00709-0

6
Standardising MET amplification testing: limitations of the GCN ≥6 criterion Repl

Author:Wu, Yi-Long; Yao, Yu; Zhang, Pei-Long; Shi, He-Peng

Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 3, pp. e128-e128. DOI:

7
Standardising MET amplification testing: limitations of the GCN ≥6 criterio

Author:Liu, Yuxin; Zhang, Dingdan; Tian, Shaodan

Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 3, pp. e127-e127. DOI: 10.1016/S1470-2045(25)00758-2

8
International Multidisciplinary Consensus Group for Malignant Spinal Cord Compression: recommendations for definitions, reporting items, and study endpoints for clinical trials and audit

Author:Wong, Henry C. Y.; Choi, J. Isabelle; Marta, Gustavo Nader; Lee, Shing Fung; Chan, Adrian Wai; Santos, Monica D'alma Costa; Leung, Sheona; Wong, Edmond; Chan, Stephanie; Hircock, Caroline; Raman, Srinivas; Oldenburger, Eva; Simone Ii, Charles B.; Dearnaley, David; Maranzano, Ernesto; Chow, Edward; Rades, Dirk; Hoskin, Peter

Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 2, pp. e111-e122. DOI: 10.1016/S1470-2045(25)00602-3

9
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 tria

Author:Zhang, Liang; Zhang, Xiqin; Wu, Lin; Xing, Wenqun; Liu, Chunling; Zhang, Peng; Chen, Kai; Shi, Jianhua; Xu, Shidong; Zhang, Xiaodong; Dong, Xiaorong; Fang, Haohui; Yu, Xinmin; Gao, Yang; Li, Gaofeng; Chen, Zhenming; Fan, Shaonan; Zhang, Xiaoqing; Cheng, Ying

Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 2, pp. 159-168. DOI: 10.1016/S1470-2045(25)00643-6

10
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 tria

Author:Einsele, Hermann; San-Miguel, Jesus; Dhakal, Binod; Touzeau, Cyrille; Leleu, Xavier; Donk, Niels Wcj Van De; Sidana, Surbhi; Oriol, Albert; Cohen, Yael C.; Harrison, Simon J.; Mateos, Maria-Victoria; Martinez-Lopez, Joaquin; Corradini, Paolo; Karlin, Lionel; Chen, Diana; Li, Quanlin; Yeh, Tzu-min; Li, Katherine; Plaks, Vicki; Slaughter, Ana; Lonardi, Carolina; Benachour, Nina; Ghosh, Arnab; Vogel, Martin; Schecter, Jordan M.; Lendvai, Nikoletta; Koneru, Mythili; Patel, Nitin; Florendo, Erika; Ho, Phoebe Joy; Popat, Rakesh

Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 2, pp. 254-268. DOI: 10.1016/S1470-2045(25)00653-9


在线咨询

Lancet Oncology

国际简称:LANCET ONCOL参考译名:柳叶刀肿瘤学

年发文量:174 CiteScore:42 是否预警:否 Gold OA文章占比:16.03% 研究类文章占比:79.89%

杂志社联系方式:ELSEVIER SCIENCE INC, 360 PARK AVE SOUTH, NEW YORK, USA, NY, 10010-1710

Lancet Oncology